ClinicalTrials.gg
CompletedNCT02469155Updated Oct 2, 2025Results posted

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

A Phase 3 interventional study of ITI-007 and Risperidone in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
696
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
Largest of 12
696 · median 66
Started
2015
the only one that year
Phase 3
5 of 12
2 open now
Registered
4th of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one has the largest enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
  • experiencing an acute exacerbation of psychosis

Exclusion criteria

Exclusion Criteria:

  • any subject unable to provide
  • any female subject who is pregnant or breast-feeding
  • any subject judged to be medically inappropriate for study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
696 participants (actual)

Study arms

  • Experimental
    Lumateperone 14 mg (ITI-007 20 mg Tosylate)

    Lumateperone 14 mg (ITI-007 20 mg Tosylate) administered orally as formulated capsules once daily for 6 weeks

    Drug: ITI-007

  • Experimental
    Lumateperone 42 mg (ITI-007 60 mg Tosylate)

    Lumateperone 42 mg (ITI-007 60 mg Tosylate) administered orally as formulated capsules once daily for 6 weeks

    Drug: ITI-007

  • Placebo comparator
    Placebo

    Placebo administered orally as visually-matched capsules once daily for 6 weeks

    Drug: Placebo

  • Active comparator
    Risperidone

    Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks

    Drug: Risperidone

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

    Time frame: 6 weeks

Secondary outcomes

  1. Change From Baseline to Week 6 in Clinical Global Impressions-Severity of Illness Scale

    The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."

    Time frame: 6 weeks

07

Results

Posted Oct 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneLumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidone
Started174174174174
Completed113128133105
Not completed61464169
Withdrew: Adverse event60110
Withdrew: Lack of efficacy1310108
Withdrew: Death0001
Withdrew: Lost to follow-up5272
Withdrew: Physician decision0010
Withdrew: Withdrawal by subject34302037
Withdrew: Other33210
Withdrew: Protocol violation0101

Outcome measures

PrimaryChange From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

Time frame:
6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
units on a scaleLumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidone
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score-15.0 ± 1.27-14.6 ± 1.23-15.1 ± 1.21-20.5 ± 1.33
Statistical analysis
  • Lumateperone 14 mg (ITI-007 20 mg Tosylate) vs Placebo · Mixed Models for Repeated Measure · p = 0.972 · Least squares mean difference: 0.1 · 95% CI -3.39 to 3.51
  • Lumateperone 42 mg (ITI-007 60 mg Tosylate) vs Placebo · Mixed Effects Model for Repeated Measure · p = 0.789 · Least squares mean difference: 0.5 · 95% CI -2.92 to 3.84
SecondaryChange From Baseline to Week 6 in Clinical Global Impressions-Severity of Illness Scale

The Clinical Global Impressions (CGI) Scale is a standardized assessment tool that the clinician can use to rate the severity of illness, change over time, and efficacy of medication, taking into account the subject's clinical condition and the severity of side effects. The CGI Scale consists of 3 global subscales, only one of which was used in the present study. The first subscale, Severity of Illness (CGI-S), assesses the clinician's impression of the subject's current illness state; it is often used both before and after treatment. Scores on the Severity of Illness subscale range from 1 = "not ill" at all to 7 = "among the most extremely ill."

Time frame:
6 weeks

Results for this outcome have not been posted.

Adverse events

Collected over From signing ICF until end of study procedures (~10 weeks), including 6 weeks of double blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 14 mg (ITI-007 20 mg Tosylate)0/172 (0%)0/172 (0%)57/172 (33.1%)
Lumateperone 42 mg (ITI-007 60 mg Tosylate)0/172 (0%)1/172 (0.6%)76/172 (44.2%)
Placebo0/178 (0%)0/178 (0%)68/178 (38.2%)
Risperidone1/173 (0.6%)0/173 (0%)79/173 (45.7%)
Most frequent serious events
Most frequent serious events
EventLumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidone
AgitationPsychiatric disorders0/1721/1720/1780/173
Most frequent other events
Most frequent other events
EventLumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidone
HeadacheNervous system disorders16/17236/17225/17836/173
SomnolenceNervous system disorders19/17231/17211/17830/173
ConstipationGastrointestinal disorders10/17212/17217/1787/173
NauseaGastrointestinal disorders7/17216/1728/17815/173
SedationNervous system disorders11/1727/1725/17814/173
Weight IncreasedInvestigations5/1723/1724/17811/173
ToothacheGastrointestinal disorders5/1727/17211/1788/173
DyspepsiaGastrointestinal disorders6/1729/17210/1783/173
Dry MouthGastrointestinal disorders4/1729/1720/1787/173

Baseline characteristics

4 subjects received an incorrect treatment compared to that which they were randomized. The numbers presented in Baseline Characteristics are as treated in each group except as noted.

Age, Continuous
Age, Continuous(years)Lumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidoneTotal
Mean42.7 ± 9.9941.9 ± 9.8843.5 ± 9.9042.4 ± 10.7742.6 ± 10.13
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidoneTotal
Female47494641183
Male125123132132512
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidoneTotal
White26303540131
Back or African American140140133123536
Asian20327
Other427821
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(units on a scale)Lumateperone 14 mg (ITI-007 20 mg Tosylate)Lumateperone 42 mg (ITI-007 60 mg Tosylate)PlaceboRisperidoneTotal
Mean88.7 ± 9.8690.9 ± 10.2690.0 ± 9.8190.0 ± 9.6089.9 ± 9.89
08

Study locations

11 sites
  • Clinical Site
    Little Rock, Arkansas, United States
  • Clinical Site
    Springdale, Arkansas, United States
  • Clinical Site
    Culver City, California, United States
  • Clinical Site
    Lemon Grove, California, United States
  • Clinical Site
    Long Beach, California, United States
  • Clinical Site
    San Diego, California, United States
  • Clinical Site
    North Miami, Florida, United States
  • Clinical Site
    Berlin, New Jersey, United States
  • Clinical Site
    Marlton, New Jersey, United States
  • Clinical Site
    Austin, Texas, United States
  • Clinical Site
    Dallas, Texas, United States
09

References and documents

Publications

  • Citrome L, Durgam S, Edwards JB, Davis RE. Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J Clin Psychiatry. 2023 Mar 6;84(2):22r14631. doi: 10.4088/JCP.22r14631. PubMed 36883881 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2025, 9 years 2 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2015
First posted
Jun 11, 2015
Start
Jun 2015
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results delay requested
Nov 8, 2017
Results first posted
Oct 2, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02469155
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jun 2015
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Oct 2, 2025
Last update
Oct 2, 2025

Study contacts

Kimberly Vanover, Ph.D.
study director · Intra-Cellular Therapies, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion